生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK4139 生物科技

交易中 03-03 11:31:11 EST

1,149.46

-26.63

-2.26%

最高1,176.09	最低1,143.00	成交量2.46亿
今开1,176.09	昨收1,176.09	日振幅2.81%
总市值0.00	流通市值0.00	总股本0.00
成交额48.15亿	换手率--	流通股本0.00
市净率7.364132	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"生物科技","latestPrice":1149.4567,"timestamp":1772555470982,"preClose":1176.0862,"halted":0,"volume":245589111,"delay":0,"changeRate":-0.022642,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-26.629517,"latestTime":"03-03 11:31:11 EST","open":1176.0856,"high":1176.0856,"low":1142.9974,"amount":4814575697.720185,"amplitude":0.028134,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1772571600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":7.364132,"peRate":-194.2153,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK4139","defaultTab":"news","newsList":[{"id":"2616297723","title":"首次全年盈利，百济神州为何股价三地齐跌？","url":"https://stock-news.laohu8.com/highlight/detail?id=2616297723","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616297723?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:49","pubTimestamp":1772549340,"startTime":"0","endTime":"0","summary":"中新网北京3月3日电(记者赵方园)一度被冠以“烧钱一哥”的A股创新药龙头百济神州，终于在2025年迎来了历史性转折。近期，百济神州发布2025年度业绩快报，报告期内实现营业总收入382.05亿元，同比增长40.4%；归属于上市公司股东的净利润14.22亿元。而在2024年同期，公司亏损49.78亿元。这是百济神州成立十六年以来首次实现全年盈利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603033660707240.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603033660707240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1251922891.USD","LU0588546209.SGD","BK1583","BK1500","LU0307460666.USD","LU2328871848.SGD","LU1969619763.USD","688235","ONC","06160","LU1303224171.USD","BK4588","BK4139","LU1770034418.SGD","LU1719994722.HKD","BK1588","BK4585","BK4526","BK0239","BK1161"],"gpt_icon":0},{"id":"2616872325","title":"密苏里大学研发“DNA硬盘”，可反复擦除和重写","url":"https://stock-news.laohu8.com/highlight/detail?id=2616872325","media":"IT之家","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616872325?lang=zh_cn&edition=full","pubTime":"2026-03-03 21:51","pubTimestamp":1772545911,"startTime":"0","endTime":"0","summary":"IT之家 3 月 3 日消息，密苏里大学 目前正在研发一款“DNA 硬盘”，据称这项技术“让该领域朝着实用、可擦写的系统又迈进了一步”。遗憾的是，密苏里大学关于这项 DNA 硬盘进展的博客文章技术细节相当匮乏，也并未公布任何原型照片、演示数据或上市时间等信息。顾教授团队宣称，他们研发出了一种可反复存储、擦除和重写 DNA 数据的方法。项目方希望将 DNA 硬盘缩小到 U 盘大小，不过目前外界连非迷你版的原型机和演示都尚未见到。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8rCV7FydTf0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"ifeng_tech","symbols":["DNA","BK4109","BK4121","BK4139"],"gpt_icon":0},{"id":"1170463595","title":"Propanc Biopharma主力资产PRP在临床前胰腺癌模型中显示超过85%的肿瘤生长抑制率","url":"https://stock-news.laohu8.com/highlight/detail?id=1170463595","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170463595?lang=zh_cn&edition=full","pubTime":"2026-03-03 21:48","pubTimestamp":1772545721,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. (OTC: PPCB) 宣布，其领先研发资产PRP在针对胰腺癌的临床前研究模型中，展现出超过85%的肿瘤生长抑制效果。这一积极数据进一步验证了PRP作为潜在抗癌疗法的有效性，特别是在治疗胰腺癌这一难治性癌症领域显示出巨大潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"gpt_icon":0},{"id":"1189079805","title":"TransCode Therapeutics与Unleash达成协议，后者将获113.6万股优先股","url":"https://stock-news.laohu8.com/highlight/detail?id=1189079805","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189079805?lang=zh_cn&edition=full","pubTime":"2026-03-03 21:13","pubTimestamp":1772543599,"startTime":"0","endTime":"0","summary":"根据双方达成的协议条款，Unleash将获得TransCode Therapeutics发行的1,136,364股优先股。此次股权安排标志着两家公司在战略合作层面取得重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAZ","BK4539","BK4139"],"gpt_icon":0},{"id":"1197207844","title":"Arcutis启动Arq-234一期1a/1b研究入组，评估CD200R激动剂在健康志愿者及特应性皮炎成人患者中的效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1197207844","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197207844?lang=zh_cn&edition=full","pubTime":"2026-03-03 21:06","pubTimestamp":1772543187,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics Inc. (ARQT) 已正式启动其候选药物Arq-234的一期1a/1b临床研究，并开始招募受试者。该项研究旨在评估这款CD200R激动剂在健康志愿者以及患有特应性皮炎的成人群体中的安全性与耐受性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"1128008188","title":"应急生物解决方案公司宣布任命小约翰·D·福勒为董事会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=1128008188","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128008188?lang=zh_cn&edition=full","pubTime":"2026-03-03 21:05","pubTimestamp":1772543129,"startTime":"0","endTime":"0","summary":"马里兰州盖瑟斯堡，2026年3月3日——应急生物解决方案公司今日宣布，任命小约翰·D·福勒为其董事会成员，该任命自2026年3月1日起生效。福勒先生在医疗健康和金融服务领域拥有超过三十年的领导经验。他将任职于审计与财务委员会。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EBS","BK4583","BK4139"],"gpt_icon":0},{"id":"1149822474","title":"协和麒麟：数周内安全审查揭示恶性肿瘤新风险，或与病毒及免疫因素相关","url":"https://stock-news.laohu8.com/highlight/detail?id=1149822474","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149822474?lang=zh_cn&edition=full","pubTime":"2026-03-03 21:05","pubTimestamp":1772543110,"startTime":"0","endTime":"0","summary":"协和麒麟公司近期完成的安全评估显示，在过去数周的分析中发现新型恶性肿瘤风险信号，这些潜在病例可能与病毒感染或免疫系统异常存在关联。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4533","LU0122379950.USD","LU0889565916.HKD","SG9999001440.SGD","IE00B2B36J28.USD","AMGN","LU0868494617.USD","LU0058720904.USD","IE0009355771.USD","LU2468319806.SGD","LU0109394709.USD","BK4585","LU1023059063.AUD","BK4534","IE00B4R5TH58.HKD","IE0002141913.USD","LU1983299246.USD","LU2242646821.SGD","LU0289739699.SGD","LU1061106388.HKD","LU1571399168.USD","IE00BJJMRZ35.SGD","BK4588","BK4599","BK4139","LU2242652126.USD","BK4566","LU2112291526.USD","LU2089984988.USD","LU1057294990.SGD","IE00BFTCPJ56.SGD","LU0320765992.SGD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"1146152400","title":"万达生物制药宣布美国FDA为Hetlioz®时差障碍适应症召开里程碑式听证会，系40余年来首次新药审批听证","url":"https://stock-news.laohu8.com/highlight/detail?id=1146152400","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146152400?lang=zh_cn&edition=full","pubTime":"2026-03-03 21:04","pubTimestamp":1772543085,"startTime":"0","endTime":"0","summary":"万达生物制药宣布，美国食品药品监督管理局已为其药物Hetlioz®用于治疗时差障碍的申请召开了一次具有里程碑意义的听证会。此次听证会是FDA超过40年来首次针对新药审批举行的听证会，标志着监管程序的一个重要突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"gpt_icon":0},{"id":"1129046632","title":"Absci任命Ransi Somaratne博士为首席医疗官，强化临床领导团队","url":"https://stock-news.laohu8.com/highlight/detail?id=1129046632","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129046632?lang=zh_cn&edition=full","pubTime":"2026-03-03 21:04","pubTimestamp":1772543062,"startTime":"0","endTime":"0","summary":"人工智能药物发现公司Absci Corporation. (ABSI) 宣布了一项重要人事任命，旨在加强其临床开发实力。公司已正式任命Ransi Somaratne博士，FACC，MBA为其首席医疗官。Somaratne博士在心血管疾病和代谢紊乱等领域的临床开发方面拥有超过二十年的丰富经验，他的加入将为Absci利用人工智能平台加速创新疗法开发的战略提供关键的临床领导力。\n此次任命凸显了Absci致力于将其人工智能生成的治疗候选药物高效推向临床阶段的决心。Somaratne博士深厚的医学背景和行业经验预计将显著推动公司的管线进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4121","BK4539","ABSI"],"gpt_icon":0},{"id":"1165109744","title":"Acumen Pharmaceuticals将在2026年阿尔茨海默病与帕金森病国际会议上展示阿尔茨海默病治疗新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=1165109744","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165109744?lang=zh_cn&edition=full","pubTime":"2026-03-03 21:03","pubTimestamp":1772543027,"startTime":"0","endTime":"0","summary":"Acumen Pharmaceuticals, Inc. (ABOS) 宣布，其将在2026年举行的阿尔茨海默病与帕金森病国际会议（International Conference on Alzheimer’s and Parkinson’s Diseases）上，公布公司在阿尔茨海默病治疗领域取得的最新研究进展。\n此次展示将重点聚焦于该公司在研疗法的最新数据，标志着其在攻克这一神经退行性疾病道路上迈出的关键一步。业界期待这些数据能为阿尔茨海默病的治疗带来新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABOS","BK4139","BK4539"],"gpt_icon":0},{"id":"1192716609","title":"Passage Bio公司：推进亨廷顿病差异化临床前项目，预计2026年下半年选定临床候选药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1192716609","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192716609?lang=zh_cn&edition=full","pubTime":"2026-03-03 20:11","pubTimestamp":1772539872,"startTime":"0","endTime":"0","summary":"Passage Bio公司正在积极推进其针对亨廷顿病的差异化临床前研发项目。该项目取得显著进展，公司预计将在2026年下半年完成临床候选药物的遴选工作。\n这一重要里程碑标志着公司在神经科学领域基因治疗研发方面迈出关键一步。候选药物的确定将为后续临床开发奠定坚实基础，有望为亨廷顿病患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PASG","BK4139"],"gpt_icon":0},{"id":"1175985973","title":"Priovant宣布FDA受理并授予Brepocitinib治疗皮肌炎新药申请优先审评资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1175985973","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175985973?lang=zh_cn&edition=full","pubTime":"2026-03-03 20:00","pubTimestamp":1772539222,"startTime":"0","endTime":"0","summary":"生物制药公司Priovant今日宣布，美国食品药品监督管理局（FDA）已正式受理其口服TYK2/JAK1抑制剂Brepocitinib用于治疗成人皮肌炎的新药申请（NDA），并授予该申请优先审评资格。\n此次优先审评标志着Brepocitinib在针对这一罕见、衰弱性自身免疫性疾病的研发进程中迈出了关键一步。若获批，该药物有望为皮肌炎患者提供一种新的重要治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ROIV"],"gpt_icon":0},{"id":"1130566079","title":"Scholar Rock公布2025年第四季度及全年财务业绩与近期业务亮点","url":"https://stock-news.laohu8.com/highlight/detail?id=1130566079","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130566079?lang=zh_cn&edition=full","pubTime":"2026-03-03 20:00","pubTimestamp":1772539221,"startTime":"0","endTime":"0","summary":"生物制药公司Scholar Rock Holding Corp（简称：Scholar Rock）近日发布了其2025年第四季度及全年的财务报告，并同步更新了公司在业务层面的重要进展。此次公布的信息涵盖了公司在特定报告期内的财务表现以及研发管线和战略合作等方面的最新动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRRK","BK4139"],"gpt_icon":0},{"id":"1161672323","title":"Tonix Pharmaceuticals 获纳斯达克批准，将从纳斯达克资本市场转板至纳斯达克全球精选市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1161672323","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161672323?lang=zh_cn&edition=full","pubTime":"2026-03-03 19:11","pubTimestamp":1772536263,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals Holding Co (TNXP) 已正式获得纳斯达克交易所的批准，将其普通股的上市资格从纳斯达克资本市场转移至纳斯达克全球精选市场。\n此次转板标志着公司达到了更高的上市标准，通常意味着更强的财务表现和更严格的治理要求。这一变动预计将提升公司在全球投资者中的知名度和吸引力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4139","TNXP"],"gpt_icon":0},{"id":"1103779071","title":"Karyopharm Therapeutics修订融资条款 取消50%资金用于提升最低流动性要求的限制","url":"https://stock-news.laohu8.com/highlight/detail?id=1103779071","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103779071?lang=zh_cn&edition=full","pubTime":"2026-03-03 19:06","pubTimestamp":1772535977,"startTime":"0","endTime":"0","summary":"Karyopharm Therapeutics Inc.近日宣布，已成功完成对其融资协议的修订。根据最新条款，公司取消了原有协议中要求将50%融资收益专项用于提高最低流动性承诺的规定。这一调整将为Karyopharm提供更灵活的资金运用空间，使其能够根据研发进展和商业需求更高效地配置资源。通过解除资金使用限制，Karyopharm可以更自主地决定将融资款项投入最具潜力的领域，包括创新药物研发、临床试验推进以及商业化布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KPTI","BK4139"],"gpt_icon":0},{"id":"1101404919","title":"Karyopharm Therapeutics Inc. 修订协议允许公司延期付款至2026年9月——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1101404919","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101404919?lang=zh_cn&edition=full","pubTime":"2026-03-03 19:04","pubTimestamp":1772535854,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的一份文件，Karyopharm Therapeutics Inc. 已通过一项修订协议，获得将特定款项的支付期限推迟至2026年9月的许可。此项安排为公司提供了更灵活的财务运营空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KPTI","BK4139"],"gpt_icon":0},{"id":"2616923983","title":"火爆！HALO交易席卷全球","url":"https://stock-news.laohu8.com/highlight/detail?id=2616923983","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616923983?lang=zh_cn&edition=full","pubTime":"2026-03-03 11:38","pubTimestamp":1772509080,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　HALO交易席卷全球资本市场，硬资产成资金避险新宠。　　2026年以来，全球资本市场掀起一股“硬资产”投资热潮，HALO交易从华尔街快速蔓延至A股，成为当前市场最受关注的交易策略。　　HALO交易作为高盛、摩根士丹利等国际顶级投行2026年初主推的核心策略，迅速成为华尔街乃至全球资金的配置焦点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/marketresearch/2026-03-03/doc-inhpspms7665771.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2026-03-03/doc-inhpspms7665771.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HALO","LU0053671581.USD","BK4139"],"gpt_icon":0},{"id":"2616966003","title":"FDA要求开展III期试验 uniQure(QURE.US)亨廷顿病基因疗法上市受阻股价重挫约33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616966003","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616966003?lang=zh_cn&edition=full","pubTime":"2026-03-03 09:50","pubTimestamp":1772502622,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，基因治疗公司uniQure原本寄望其亨廷顿病候选药物AMT-130能获得美国FDA的加速批准，但这一期望近日落空。FDA明确告知这家生物制药公司，需开展一项随机、双盲、假手术对照的III期临床试验。受此消息影响，公司股价周一收盘大跌约33%。根据公司发布的新闻稿，uniQure此前计划基于一项与外部对照比较的I/II期研究数据申请批准。uniQure表示，将在第二季度请求与FDA召开B类会议，商讨后续推进路径。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409276.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","III","BK4134","LU0320765992.SGD","QURE","LU0889565916.HKD","LU0109394709.USD"],"gpt_icon":0},{"id":"2616398750","title":"微软推SER技术提升光追性能，RTX 4090帧率增40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616398750","media":"DoNews","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616398750?lang=zh_cn&edition=full","pubTime":"2026-03-03 08:26","pubTimestamp":1772497563,"startTime":"0","endTime":"0","summary":"2026年3月1日，微软在最新DirectX更新中引入着色器执行重排序（SER）技术，旨在优化光线追踪效率。该技术通过重新排列光线击中物体的着色器调用顺序，减少线程同步等待，降低硬件空闲时间。测试显示，英特尔Battlemage显卡帧率提升90%，英伟达RTX 4090提升40%。SER已集成至Shader Model 6.9规范，需AgilitySDK 1.619启用。目前支持Ada Lovelace及更新架构GPU，但实际游戏表现或低于测试峰值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303082623a443e2e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303082623a443e2e9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4503","LU1506573853.SGD","LU0198837287.USD","LU2362541273.HKD","IE00BJLML261.HKD","LU1430594728.SGD","LU2023250504.SGD","LU1582986433.USD","LU1989772923.USD","LU0894485498.HKD","MSFW","BK4581","LU2168564149.EUR","LU2357305700.SGD","LU0234572021.USD","LU0861579265.USD","IE00BN8TJ469.HKD","LU2125909593.SGD","LU2125154778.USD","LU2756315664.SGD","LU1003077747.HKD","IE00BSNM7G36.USD","IE00BKDWB100.SGD","LU1116320737.USD","IE000ITXATA3.USD","IE000W1ABFV2.USD","LU1435385759.SGD","LU2237443465.HKD","LU1642822529.SGD","LU1691799644.USD","LU1323610961.USD","MSFU","LU0823421416.USD","SG9999015341.SGD","LU0642271901.SGD","LU1366192091.USD","LU2244417387.USD","IE0001KFT4U8.USD","IE00B3S45H60.SGD","LU2242649171.HKD","LU1551013425.SGD","LU0265550359.USD","LU0289739343.SGD","SG9999014559.SGD","LU0640476718.USD","LU0109391861.USD","LU0726765562.USD","LU0784383803.USD","LU2237443622.USD","LU2362541513.USD","LU1989764664.SGD","BK4543","LU1868837300.USD","LU1267930813.SGD","LU1791710582.SGD","LU0069063385.USD","LU1814569148.SGD","LU1064131342.USD","LU0124676726.USD","LU0234570918.USD","LU1069344957.HKD","LU2491050154.USD","LU1983260115.SGD","LU0312595415.SGD","LU0545039389.USD","LU1244550577.SGD","LU2452424414.USD","LU2108987350.USD","LU2506952097.USD","LU1181866309.USD","LU0683600562.USD","LU0820562030.AUD","LU1923622614.USD","LU2433249047.HKD","LU1119994496.HKD","BK4554","LU1629891620.HKD","LU1035773651.USD","LU1674673428.USD","LU0957791311.USD","LU0545562505.USD","SG9999000418.SGD","LU0210528500.USD","LU1935043536.SGD","LU2237443549.SGD","LU0310800379.SGD","LU1917777945.USD","LU0128525929.USD","IE00B1XK9C88.USD","LU1340139317.AUD","LU1815333072.USD","LU1935042215.USD","LU0211327993.USD","LU1923623000.USD","IE000KEQY171.SGD","LU0784385170.HKD","IE00B7KXQ091.USD","LU0127658192.USD","IE0004086264.USD","LU1221951129.SGD","LU1670710588.SGD","SGXZ31699556.SGD","LU1236620750.USD","LU2041044095.USD","LU2133065610.SGD","SG9999014880.SGD","LU1043141396.HKD","BK4592","LU2236285917.USD","BK4587","LU2417539215.USD","BK4525","IE0005OL40V9.USD","LU0345774631.USD","LU0879622024.SGD","LU1121112475.USD","LU1236620834.HKD","LU1674673691.USD","SGXZ51526630.SGD","LU0342679015.USD","LU2347655156.SGD","IE00BJJMRX11.SGD","LU2087625088.SGD","LU0310799852.SGD","SG9999015358.SGD","LU2097829019.USD","LU2552382215.SGD","LU1935043023.USD","LU0265550946.USD","LU0795875086.SGD","LU0072462426.USD","BK4598","LU0080751232.USD","LU0289941410.SGD","LU1267930730.SGD","LU2148611432.USD","SG9999014575.USD","LU1551013342.USD","SG9999015952.SGD","LU2764263203.CNY","IE00B775H168.HKD","IE00BLSP4239.USD","LU0302445910.USD","LU1564329628.SGD","LU2092937148.SGD","BK4535","LU1228905037.USD","IE00BQXX3F31.USD","SG9999001424.SGD","LU0187121727.USD","LU2271345857.HKD","LU0097036916.USD","LU0162691827.USD","LU0320765646.SGD","LU1069347547.HKD","LU0965509283.SGD","LU1582987324.SGD","LU1633808545.USD","LU0354030511.USD","LU1868836757.USD","LU0965509010.AUD","LU2275660780.HKD","LU2242650005.HKD","LU0107464264.USD","LU2326559502.SGD","SG9999015986.USD","LU0949170772.SGD","LU0868494617.USD","LU2265009873.SGD","LU0345769128.USD","LU0894486033.HKD","LU1974910355.USD","LU1732800096.USD","RTXG","LU0472753341.HKD","LU0757359954.USD","MSFO","LU1815336760.USD","LU0690374615.EUR","IE0003U64NQ7.SGD","LU0096364046.USD","LU2462157665.USD","LU1032466523.USD","LU1035775433.USD","BK4579","LU0061474705.USD","LU0175139822.USD","LU1127390331.HKD","LU2063271972.USD","IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","LU1582986359.USD","LU2065171402.SGD","BK4588","LU2381873111.SGD","LU1066053197.SGD","LU2360032135.SGD","BK4538","LU0795875169.SGD","IE00BYXW3230.USD","MSFL","LU0210533765.USD","LU1935042991.SGD","LU0210536198.USD","LU2430703251.USD","IE00BJJMRY28.SGD","LU2247934214.USD","IE00B3SWFQ91.USD","IE00BJTD4V19.USD","LU0417517546.SGD","LU1244550494.USD","LU1670711123.USD","LU1037948541.HKD","LU1868837136.USD","LU2471134952.CNY","LU2023250330.USD","LU0215105999.USD","LU2487616109.SGD","LU1162221912.USD","LU0661504455.SGD","LU2237443895.HKD","LU2746668461.USD","IE0009G5SDU7.USD","IE00BMPRXN33.USD","IE00B4YYXB79.USD","LU1334329650.SGD","LU1868836591.USD","LU0029864427.USD","LU2413666426.HKD","LU2552382132.HKD","IE00B5TLWC47.USD","LU1914381329.SGD","IE00BFSS8Q28.SGD","LU1582987597.SGD","LU2362540622.SGD","LU2456880835.USD","BK4187","LU0314106906.USD","BK4532","LU0251132253.USD","LU1670627923.USD","IE0009356076.USD","SG9999015978.USD","LU1548497426.USD","LU1934455863.HKD","HK0000914686.HKD","LU2097344431.USD","LU2210150020.SGD","LU0353189763.USD","LU1316542783.SGD","SG9999002224.SGD","LU0964807845.USD","IE00BBT3K403.USD","IE0034235295.USD","LU2756315318.SGD","SG9999018865.SGD","LU0950375773.USD","LU2896262040.SGD","LU2458330169.SGD","LU0949170426.SGD","LU2420271590.USD","LU0348723411.USD","LU0308772762.SGD","LU1066051225.USD","LU1145028129.USD","BK4576","LU1221951046.USD","GB00B4LPDJ14.GBP","SG9999014542.SGD","IE00BK4W5L77.USD","LU2077746001.SGD","LU2403377893.USD","LU2463028550.USD","LU0061474960.USD","LU0323591593.USD","LU2168563687.JPY","LU1153585028.USD","LU0109392836.USD","LU1496350171.SGD","LU0672654240.SGD","LU1951200564.SGD","IE00B19Z8X17.USD","LU1989773731.SGD","LU0057025933.USD","LU0267386448.USD","LU1778281490.HKD","LU0882574139.USD","SG9999004303.SGD","LU2404859667.USD","IE00BK4W5M84.HKD","LU1429558221.USD","LU2279689827.SGD","LU0095938881.EUR","LU2023251221.USD","LU2237957811.SGD","IE0004445239.USD","LU0320765059.SGD","LU0345768153.USD","IE00B4JS1V06.HKD","LU2092937221.SGD","LU2746668974.SGD","LU1564329461.SGD","LU0157215616.USD","LU0006306889.USD","LU1043141123.HKD","IE00BDCRKT87.USD","LU1235295455.SGD","LU2750360997.AUD","LU0528227936.USD","LU0724617625.USD","LU0957808578.USD","LU0158827781.USD","LU1066051811.HKD","IE0034235303.USD","IE00B1BXHZ80.USD","LU1988902786.USD","SGXZ23171101.USD","LU1244550221.USD","IE00BDRTCR15.USD","LU1116320901.HKD","LU0276348264.USD","LU2168564222.USD","IE00BJTD4N35.SGD","IE00BKVL7J92.USD","LU0011850046.USD","LU2191332357.HKD","LU0690374961.EUR","LU2413666699.HKD","LU2237443978.SGD","LU0171293334.USD","LU0053666078.USD","LU0444971666.USD","LU2089284900.SGD","LU2471134796.USD","LU2213496289.HKD","SGXZ99366536.SGD","LU0077335932.USD","LU0106261372.USD","LU1929549753.HKD","LU1989772840.SGD","LU0719512351.SGD","LU2860962120.EUR","GB00BDT5M118.USD","LU0238689110.USD","LU1934455194.USD","LU1989764748.USD","BK4527","BK4612","LU1564329032.USD","LU0820561818.USD","LU2471134523.USD","LU0823417653.USD","SG9999014567.USD","LU2237438978.USD","LU0266013472.USD","LU0345769631.USD","LU0965509101.SGD","LU0912757837.SGD","LU1721428933.USD","LU0557290698.USD","LU0390134368.USD","LU2506952170.USD","LU0203202063.USD","LU1935042488.USD","LU2360108059.USD","LU0788109477.HKD","LU1720051108.HKD","LU0553294199.USD","LU0689626769.HKD","LU0094547139.USD","LU0316494557.USD","LU0345774391.USD","MSFX","IE00BMPRXQ63.HKD","LU2125909247.SGD","LU2298321311.HKD","LU0689472784.USD","LU2065169927.USD","LU0072461881.USD","LU2361044865.SGD","LU0823421333.USD","SG9999015945.SGD","LU1803068623.USD","IE00B775SV38.USD","LU0889566641.SGD","LU2360106780.USD","LU0871640123.AUD","SG9999001077.SGD","LU0323240290.USD","BK4567","LU2092627202.USD","LU1564329115.USD","LU2764263039.SGD","LU0154236417.USD","LU1301847155.USD","LU2210149790.SGD","IE00B19Z8W00.USD","LU0289960550.SGD","LU0494093205.USD","LU1074936037.SGD","LU2083900584.USD","LU0960925559.SGD","LU0048584097.USD","LU0353189680.USD","LU1989763005.USD","LU0096362180.USD","LU2506951875.HKD","SG9999018857.SGD","LU0738911758.USD","LU2430703095.HKD","LU0345770308.USD","LU1084165304.USD","LU2471134879.HKD","LU1804176565.USD","BK4533","LU1366333091.USD","SG9999014898.SGD","LU1232071149.USD","IE00BFXG0V08.USD","HK0000914660.USD","IE00BMPRXR70.SGD","LU0456855351.SGD","LU0347712357.USD","LU0476273544.USD","LU0965508806.USD","LU1066051498.USD","LU2097344357.USD","LU1032955483.USD","LU1670711040.USD","LU1718418525.SGD","LU2347655073.USD","BK4585","LU2065171311.SGD","LU0158827948.USD","LU2750360641.GBP","LU0823417737.USD","LU0149725797.USD","LU1712237335.SGD","SG9999014914.USD","LU2461242641.AUD","LU0889565833.HKD","LU0985320562.USD","LU0784384876.USD","IE00BKPKM429.USD","IE00BN29S564.USD","LU1839511570.USD","LU0511384066.AUD","LU2125154935.USD","LU0170899867.USD","IE00BWXC8680.SGD","BK4516","LU2250418816.HKD","LU1861127337.USD","LU2286300806.USD","LU0354030438.USD","LU0708995401.HKD","SGXZ81514606.USD","MSFT","LU1934455277.USD","IE00BYQQ9H92.USD","LU2089283258.USD","LU2237443382.USD","LU0211328371.USD","LU1732799900.SGD","LU0061475181.USD","LU2764262908.HKD","LU0426412945.USD","IE00B19Z9505.USD","LU1868836914.USD","GB00B4QBRK32.GBP","LU0079474960.USD","LU2065170008.USD","LU2361045086.USD","LU2592432038.USD","LU0256863811.USD","LU2505996509.AUD","LU0466842654.USD","LU1188199696.SGD","LU0784385840.USD","LU2430703178.SGD","SG9999002232.USD","IE00BLSP4452.SGD","LU0082616367.USD","MSFY","LU2543165471.USD","LU0203201768.USD","LU2095319765.USD","LU1951198990.SGD","LU2264538146.SGD","BK4534","LU2552382058.USD","LU2087621335.USD","LU0994945656.USD","BK4504","BK4550","BK4528","BK4097","LU1585245621.USD","LU2111349929.HKD","LU0943347566.SGD","LU2023250843.SGD","LU1720051017.SGD","LU0823434740.USD","BK4139","LU0345768740.USD","BK4566","LU1852331112.SGD","LU2505996681.GBP","LU1280957306.USD","LU1623119135.USD","LU2361044949.HKD","LU0256863902.USD","LU1670628061.USD","IE00BFSS7M15.SGD","LU1496350502.SGD","LU1791710400.SGD","LU1228905540.USD","LU1037948897.HKD","LU2720916845.USD","LU0289961442.SGD","BK4577","LU2237957902.USD","LU2506951958.HKD","LU0070217475.USD","LU2404859741.USD","IE0004091025.USD","LU1803068979.SGD","LU0081259029.USD","LU0823434583.USD","IE000YTNTUN2.SGD","MSFD","LU1046421795.USD","IE0004445015.USD","SG9999014906.USD","LU2458330243.SGD","LU1571399168.USD","LU1261432733.SGD","IE00BHPRN162.USD","LU2168564065.EUR","LU1196500208.SGD","LU2168564495.EUR","LU0314104364.USD","LU1059921491.USD","LU0225283273.USD","IE00B5949003.HKD","LU0426417589.USD","LU1267930573.SGD","LU0820561909.HKD","LU2491050071.SGD","LU2491049909.HKD","BK4548","LU1670710661.SGD","LU2211815571.USD","LU0757359368.USD","LU0787776722.HKD","IE0034235188.USD","LU0323239441.USD","LU0792757196.USD","LU2054465674.USD","IE00BZ1G4Q59.USD","LU2602419157.SGD","LU2106854487.HKD","LU1235294995.USD","LU1267930490.SGD","LU2028103732.USD","LU1823568750.SGD","LU1697837992.HKD","LU0444973449.USD","LU0345770993.USD","SG9999017495.SGD","LU0708994859.HKD","LU0056508442.USD"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0081},{"period":"3month","weight":0.0071},{"period":"6month","weight":0.0662},{"period":"1year","weight":0.1552},{"period":"ytd","weight":0.0065}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"name":"生物科技","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK4139,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}